Eisai Co (4523.T) Osake Kurssi
Eisai Co Kurssi
Liikevaihto on kasvanut 1,1 % vuodessa viimeisten 19 vuoden aikana 825,38 Mrd. JPY:een. Osakekohtainen tulos on laskenut 3,1 % vuodessa viimeisten 19 vuoden aikana. Eisai Con nettomarginaali on nyt 4,7 %, laskenut 6,3 %:sta muutama vuosi sitten. Eisai Con osinkotuotto on tällä hetkellä noin 4,73 %. Jakosuhde on noin 95 % tuloksesta. Osinko on kasvanut 3,3 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 4 834,80 JPY, eli ali nykyhintaa 4,8 %. 19 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Pidä.
Eisai Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Eisai Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Eisai Co -osakkeesta
The business model of Eisai Co Ltd involves being a global pharmaceutical company focused on the discovery, development, and marketing of innovative medicines. Eisai Co Ltd aims to address unmet medical needs in areas such as neurology and oncology, along with supportive care. With a patient-centered approach, the company combines its expertise in research and development with strategic partnerships to deliver solutions for improved healthcare outcomes. Eisai Co Ltd emphasizes creating sustainable value and contributing to society through its pharmaceutical products and services.
Eisai Co Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of Eisai Co Ltd in the market include pharmaceutical companies such as Pfizer, Roche, Novartis, and Gilead Sciences.
Eisai Co Ltd is a renowned pharmaceutical company founded in 1941 in Japan. With a rich history spanning over 80 years, Eisai has established itself as a global leader in the healthcare industry. The company focuses on discovering, developing, and marketing innovative medications to address various medical needs. Eisai is committed to improving the lives of patients worldwide and has made significant contributions to research and development in the areas of neurology, oncology, and gastrointestinal disorders. Known for its dedication to patient-centered care, Eisai continues to make strides in advancing medical science and delivering effective therapeutic solutions to support human health.
Eisai Co Ltd, a renowned pharmaceutical company, has achieved notable milestones throughout its history. The company successfully developed and introduced innovative healthcare solutions, contributing to advancements in medicine. Eisai Co Ltd made significant strides in the discovery and development of drugs for various therapeutic areas, including oncology, neurology, and gastrointestinal disorders. It received numerous regulatory approvals for its groundbreaking medications, enhancing patient care worldwide. Eisai Co Ltd's relentless commitment to research and development has resulted in the introduction of groundbreaking treatments, earning recognition and trust from both healthcare professionals and patients alike.
Eisai Co Ltd is primarily present in various countries and regions across the globe. The company has significant presence in its home country, Japan, where it is headquartered. Furthermore, Eisai Co Ltd has expanded its operations to the United States, Europe, Asia, and other key markets. With its strong focus on global growth, Eisai Co Ltd has established subsidiaries and affiliates in multiple countries, enabling it to reach a wider customer base and cater to diverse markets.
Eisai Co Ltd represents a set of core values and a corporate philosophy that guides its operations. The company is committed to human health care and believes in "human health care" (hhc) as an essential principle. Eisai aims to contribute to the well-being of patients through innovative pharmaceuticals and healthcare services. The company emphasizes the importance of gaining trust from patients, healthcare professionals, and the global community while striving for continuous improvement. Eisai Co Ltd focuses on creating value for patients and society, matching scientific competence with a compassionate approach. Emphasizing patient-centricity, Eisai Co Ltd constantly endeavors to fulfill its mission of providing effective treatments and improving the quality of life for patients worldwide.
Analyytikot asettavat tällä hetkellä Eisai Co-osakkeelle keskimääräisen tavoitehinnan 4 994,86 JPY (mediaani: 4 834,80 JPY), mikä merkitsee −1,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 19 analyytikkoarvioon.
19 analyytikkoa arvioi tällä hetkellä Eisai Co-osaketta: 7 suosittaa ostoa, 11 pitoa ja 1 myyntiä.
Nykyisellä valuuttakurssilla Eisai Co-osake noteerataan hintaan 28,89 EUR (5 076,00 JPY).
Eisai Co-osake (4523.T) on listattuna 6 pörssissä, muun muassa: Tokio (JPX) (4523.T), Frankfurt (EII.F), München (EII.MU), Düsseldorf (EII.DU).
Eisai Co Ltd is a company specializing in the research, development, production, and marketing of pharmaceuticals and preparations. The Japanese company was founded in 1949 and is headquartered in Tokyo. The company is divided into several business divisions to manage its product lines. The "Neurology" division specializes in the treatment of Alzheimer's, Parkinson's, and epilepsy, offering a wide range of medications for these diseases. Eisai's "Oncology" division focuses on developing drugs for the treatment of cancer. The company works to develop innovative therapies that improve the quality of life and cure cancer patients. Products in this area include Lenvima, Halaven, and Kisplyx. Eisai's "Gastroenterology" division offers drugs for the treatment of gastrointestinal disorders, including functional dyspepsia, reflux esophagitis, enteritis, colitis, and stool regulation. This includes drugs such as Aciphex and Targaxan. Another business division of Eisai is the "Integumentary System," which focuses on products for the treatment of skin diseases such as psoriasis, acne, and atopic dermatitis. This includes products like Tazorac and Erivedge. In addition, Eisai operates its own research and development department to bring innovative drugs to the market. The company collaborates with scientific and medical partners worldwide and continuously invests in the research and development of new drugs. Furthermore, in recent years, the company has expanded its presence in the Asia-Pacific region and North America. Eisai also has joint ventures and partnerships with other companies to bring innovative products to the market, optimizing product development, production, and marketing. An example of this is the collaboration with Biogen for the development and marketing of therapies for Alzheimer's disease. Overall, Eisai specializes in providing innovative and high-quality pharmaceuticals and therapies to improve the lives of patients worldwide. The company is dedicated to research and development of new products and has a wide range of business divisions and partnerships to expand its portfolio and global presence.
liikevaihto Eisai Co on 825,38 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Eisai Co on 38,56 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Eisai Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 37,11. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Eisai Co-osakkeen arvostusta.
Eisai Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,73. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Eisai Co-osakkeen arvostuskennuslukuna.
Eisai Co:n Eulpool-laatuscore on 2/10.
Eisai Co:n ISIN on JP3160400002. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Eisai Co:n WKN on 855526. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Eisai Co:n ticker on 4523.T. Tämä pörssinoteeraus käytetään Eisai Co-osakkeiden kauppaan pörssissä.
Eisai Co osake
Eisai Co vertaisryhmä
Eisai Co Ticker
Eisai Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Eisai Co:sta
Meidän osakeanalyysimme Eisai Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Eisai Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: